Latest Period
Q2 2026
Security Snapshot
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) Institutional Ownership
CUSIP: 004890109
13F Institutional Holders and Ownership History from Q4 2022 to Q2 2026
Institutions Reporting
9
Shares (Excl. Options)
519,006
Price
$1.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Symbol
- ACRV on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 519,006
- Total 13F value
- $924,093
- Portfolio coverage rank
- 0%
- Share change
- +11,155
- Value change
- +$33,062
- Number of holders
- 9
- Shares outstanding
- 42,655,924
- SEC-reported price per share
- $2.05
- Insider filing price
- $2.05
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 004890109.
- 9 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 43 to 9 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $22,567,622 to $924,093.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 9 institutions filings for Q2 2026.
Security key
004890109
Latest holder period
Q2 2026
13F holders
9
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
ACRV full holder history
Acrivon Therapeutics, Inc. SEC filings
Acrivon Therapeutics, Inc. company facts
Acrivon Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 004890109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
ACRV
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 29% | +33% | $15,847,529 | +$5,016,666 | 12,284,906 | +46% | RA Capital Management, L.P. | 22 Apr 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.8% | $2,525,900 | 2,122,605 | Sands Capital Life Sciences Pulse Fund II, L.P. | 30 Jun 2025 |
As of 30 Jun 2026, 9 institutional investors reported holding 519,006 shares of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV). This represents 1.2% of the company’s total 42,655,924 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
Q2 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 519,006 | $924,093 | +$33,062 | $1.78 | 9 |
| 2026 Q1 | 16,236,105 | $22,567,622 | -$6,159,853 | $1.39 | 43 |
| 2025 Q4 | 18,610,735 | $44,851,327 | +$2,731,349 | $2.41 | 48 |
| 2025 Q3 | 17,461,169 | $31,603,874 | -$171,329 | $1.81 | 45 |
| 2025 Q2 | 17,802,633 | $21,184,501 | -$10,332,852 | $1.19 | 52 |
| 2025 Q1 | 22,517,048 | $45,710,668 | -$2,113,900 | $2.03 | 60 |
| 2024 Q4 | 23,250,351 | $139,966,100 | -$971,335 | $6.02 | 60 |
| 2024 Q3 | 22,960,755 | $160,726,039 | -$2,679,680 | $7.00 | 51 |
| 2024 Q2 | 23,451,873 | $136,019,583 | +$47,352,617 | $5.80 | 51 |
| 2024 Q1 | 15,245,438 | $109,005,559 | +$3,386,877 | $7.15 | 45 |
| 2023 Q4 | 14,865,624 | $73,138,289 | +$986,082 | $4.92 | 40 |
| 2023 Q3 | 15,093,861 | $144,297,342 | -$326,020 | $9.56 | 43 |
| 2023 Q2 | 15,126,531 | $196,038,750 | -$1,147,208 | $12.96 | 40 |
| 2023 Q1 | 15,216,182 | $191,059,725 | +$6,824,894 | $12.69 | 39 |
| 2022 Q4 | 14,965,637 | $170,360,092 | +$170,360,092 | $11.52 | 18 |